Publication Details - Overview

View all Online CME

Continuing Education Information

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Redefining the Role of Taxanes in Cancer Therapy: Using Technology to Take Taxanes Where No Taxanes Have Gone Before

1 AMA PRA Category 1 Credit(s)™
Release Date: August 24, 2009
Expiration Date: August 24, 2010

Publication Overview

Author

PER Editorial Staff

Overview and Purpose

Taxanes have an established role in the treatment of multiple tumor types, including breast cancer and non–small-cell lung cancer (NSCLC). Patients with either early-stage or metastatic breast cancer have achieved improved outcomes with taxane-containing regimens, although significant differences in efficacy and safety exist depending upon the specific taxane and dose schedule used. The effectiveness of taxanes is limited by the frequent development of resistance in advanced malignancies. To overcome this limitation, a new generation of taxanes with potentially improved pharmacokinetics and preferential uptake in tumors has been developed. A new taxane formulation has demonstrated improved efficacy and safety in metastatic breast cancer (MBC) compared to standard taxanes, and early-phase data for novel taxane formulations in advanced NSCLC have also shown promise. Emerging data indicate that next-generation taxanes might yield benefit in tumor types that appear insensitive to traditional taxanes, such as melanoma and pancreatic cancer.

The purpose of this activity is to apprise physicians of recent data on the use of novel taxanes and taxane formulations in the treatment of breast cancer, NSCLC, melanoma, and pancreatic cancer.

Target Audience

This educational activity is intended for medical oncologists involved in the care of patients with solid tumors. No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity.

Learning Objectives

Upon completion of this educational activity, you should be able to:

  • Discuss the current and developing role of taxane-based therapies for the treatment of NSCLC, prostate cancer, and breast cancer
  • Review the scientific rationale for the development of novel taxane-based chemotherapeutic approaches
  • Evaluate the efficacy and safety of novel taxane formulations in the treatment of patients with MBC
  • Appraise the safety and efficacy of taxane-based combination therapy for patients with metastatic melanoma
  • Compare the mechanisms of action of novel taxanes and taxane formulations in patients with locally advanced inoperable and metastatic pancreatic cancer
  • Assess the efficacy and safety of albumin-bound taxanes in the first-line treatment of advanced NSCLC

Instructions for Participation

  1. Read the following information before entering the educational activity.
  2. Complete the Pretest.
  3. Study the educational activity.
  4. Complete the Posttest.
  5. Answer the evaluation questions.
  6. After completion of the Pretest and successful completion of the Posttest and evaluation, you will receive your certificate online.

 

You will be permitted 2 attempts to successfully complete the Posttest.

The tests and evaluation must be completed by August 24, 2010, in order for you to receive your certificate.

 

Complete the test(s) and evaluation by August 24, 2010 to receive your certificate online.

Read all of the conditions in the Activity Terms box below. You must accept the CME Activity Terms in order to continue:

Disclosure Policy

It is the policy of Physicians’ Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians’ Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians’ Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

Kimberly Blackwell, MD
Research Funding – Abraxis BioScience, LLC, Bristol-Myers Squibb Company, Celsion Corporation, Genentech, Inc., GlaxoSmithKline, Pfizer Inc., Reata Pharmaceuticals Inc.; Paid Consultant – Abraxis BioScience, LLC, Novartis Pharmaceuticals Corporation, sanofi-aventis U.S.; Speaker’s Bureau – Abraxis BioScience, LLC, Novartis Pharmaceuticals Corporation, sanofi-aventis U.S.

Alexander Eggermont, MD, PhD
Research Funding – Schering-Plough Corporation; Paid Consultant – Bristol-Myers Squibb Company, Schering-Plough Corporation

Stephen E. Jones, MD
Paid Consultant – Genentech, Inc., GlaxoSmithKline, Pfizer Inc., sanofi-aventis U.S.; Speaker’s Bureau – Genentech, Inc., GlaxoSmithKline, Pfizer Inc., sanofi-aventis U.S.

Vincent Miller, MD
Paid Consultant – Abbott Laboratories, Agennix, Inc., Boehringer Ingelheim GmbH, Genentech, Inc./OSI Pharmaceuticals, Genmab, ImClone Systems Incorporated, sanofi-aventis U.S.; Other Remuneration – Abbott Laboratories, Agennix, Inc., Boehringer Ingelheim GmbH, Genentech, Inc./OSI Pharmaceuticals, Genmab, ImClone Systems Incorporated, sanofi-aventis U.S.

Caio Rocha-Lima, MD
Speaker’s Bureau – Genentech, Inc.; sanofi-aventis U.S.

Andrew Seidman, MD
Research Funding – Abraxis BioScience, LLC; Paid Consultant – Amgen, Wyeth Pharmaceuticals; Speaker’s Bureau – Abraxis BioScience, LLC

PER Editorial Staff
No relevant relationships to disclose

Satellite Symposium Faculty

Chair:

Alexander Eggermont, MD, PhD
Professor of Surgical Oncology
Head, Department of Surgical Oncology
Erasmus University Medical Center
Rotterdam, The Netherlands

Faculty:

Kimberly Blackwell, MD
Associate Professor
Departments of Medicine and Radiation Oncology
Duke University Medical Center
Durham, NC

Stephen E. Jones, MD
Medical Director, US Oncology Research
Houston, TX
Texas Oncology
Dallas, TX

Vincent Miller, MD
Associate Attending Physician
Thoracic Oncology Service
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, NY

Caio Rocha-Lima, MD
Associate Professor of Clinical Medicine
Co-Director, Phase I Unit
Co-Program Leader, Pancreatic/Hepatobiliary and Related Cancers
Co-Program Leader, Colorectal Cancer
UM/Sylvester Comprehensive Cancer Center
University of Miami Leonard M. Miller School of Medicine
Miami, FL

Andrew Seidman, MD
Attending Physician
Breast Cancer Medicine Service
Memorial Sloan-Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY

This CME activity might include discussion of investigational and/or unlabeled uses of drugs. If the activity includes discussion of investigational and/or unlabeled uses of a drug, specific information is located on the title page. Please refer to the full prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.

Commercial Support

An educational grant for this activity was provided by Abraxis BioScience.

Software Requirements

The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

PC Users
If you need to upgrade your Web browser, follow one of the links listed below:

Additional software requirements include:

Macintosh Users
Compatible Web browsers include:

Additional software requirements include:

Banner Illustration

Illustrator: Pam Curry

Disclaimer

The views and opinions expressed in this activity are those of the authors and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the authors and Physicians’ Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

Please consult full prescribing information for any drugs or procedures discussed within.

This activity is not sanctioned by, nor a part of, the 45th Annual Meeting of the American Society of Clinical Oncology.

Privacy Policy

Physicians’ Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045.

All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

©Copyright 2009 by Physicians’ Education Resource. No material may be reproduced in whole or in part, in any form, without written permission from the publisher.

All correspondence should be directed to:
Editor, Redefining the Role of Taxanes in Cancer Therapy: Using Technology to Take Taxanes Where No Taxanes Have Gone Before
Physicians’ Education Resource
3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367-3400
Fax: (214) 367-3304
E-mail: editor@cancerlearning.com

8638

Educational Grants

An educational grant for this activity was provided by:


  1. Abraxis BioScience